Latest news with #ACC
USA Today
6 hours ago
- Sport
- USA Today
Lagway among college football's top-tier QBs, per The Athletic
Expectations are high for Florida quarterback DJ Lagway as he enters his sophomore season, but could the Gators really have one of the best signal callers in all of college football? The Athletic's Grace Raynor may have answered that question while seeking clarification on her greater concern, whether the SEC features the best quarterbacks in the sport or not. A tier list of the nation's quarterbacks released earlier in the month prompted Raynor's deep dive. The SEC has five Tier 1 quarterbacks, more than double the number of those in the ACC and Big 12 conferences. An ACC quarterback, Clemson's Cade Klubnik, tops the list, but four SEC quarterbacks follow, finishing with Lagway at No. 5. Arch Manning is separated from the rest of the pack at No. 10, but he's still considered a Tier 1 quarterback. It's a blowout win for the SEC, but everyone has to live up to those expectations. Raynor poses the question: "Can 5-star recruits turn potential into reality?" Two of the highest-profile names at the position haven't played all that much. Lagway started just seven games last year, and Manning is finally set to take over the Texas offense after spending two years as Quinn Ewers' backup. If both live up to the hype, they could battle for a Heisman at some point. "Lagway, who flashed immense potential in an inconsistent debut season, may have coach Billy Napier's fate in his hands," she adds. The other Tier 1 quarterbacks on The Athletic's list are already proven. Arkansas and LSU are returning Heisman-caliber starters in Garret Nussmeier and LaNorris Sellers, respectively. Oklahoma picked up John Mateer, who wowed everyone at Washington State as a dual threat. "(Lagway) started the second half of the season, and though he made his share of freshman mistakes, he showed why he was so highly regarded, capping the year with a 300-yard performance and bowl game MVP honors," reads the tier list report from Sam Khan Jr. and Antonio Morales. "He displayed elite arm talent, good mobility and poise beyond that of a typical true freshman. His size and strength helped him keep plays alive. With Lagway behind center, the future is bright in Gainesville." Yes, Lagway is considered one of the best quarterbacks in the game, but there's an asterisk next to that distinction that the Nussmeier and Sellers types don't have. A lower-body injury could slow his start, and public opinion moves fast. A lot is riding on Lagway's performance this year, but most seem to believe that he'll live up to the task. Follow us @GatorsWire on X, formerly known as Twitter, as well as Bluesky, and like our page on Facebook to follow ongoing coverage of Florida Gators news, notes and opinions.
Fox News
6 hours ago
- Sport
- Fox News
2025 College Football Odds: Which Team Will Claim The ACC Title?
The ACC boasts more than just Clemson. Fans saw that last year with SMU and Miami (FL). So, beyond the Tigers, which other teams do oddsmakers think will have a shot at the conference title this year? Let's take a look ahead at the 2025 ACC title odds at DraftKings Sportsbook as of July 29. ACC Winner 2025-26 Clemson: +105 (bet $10 to win $20.50 total)Miami FL: +380 (bet $10 to win $48 total)SMU: +850 (bet $10 to win $95 total)Louisville: +850 (bet $10 to win $95 total)Georgia Tech: +1200 (bet $10 to win $130 total)Duke: +2500 (bet $10 to win $260 total)Florida State: +2800 (bet $10 to win $290 total)Virginia Tech: +3500 (bet $10 to win $360 total)North Carolina: +4000 (bet $10 to win $410 total)Pittsburgh: +4500 (bet $10 to win $460 total)NC State: +4500 (bet $10 to win $460 total)Syracuse: +7000 (bet $10 to win $710 total)Virginia: +8000 (bet $10 to win $810 total)Boston College: +8000 (bet $10 to win $810 total)California: +15000 (bet $10 to win $1,510 total)Wake Forest: +50000 (bet $10 to win $5,010 total)Stanford: +50000 (bet $10 to win $5,010 total) The Tigers have won the ACC nine times since 2011, and they are favored to win the title again this season. Following a dramatic 34-31 victory over SMU in last year's ACC Championship Game, the Tigers have 80% of their roster returning — the highest percentage in the nation, according to ESPN research. Last season, Clemson finished second in the conference with a 7-1 record. Next on the oddsboard is the University of Miami. Since joining the ACC in 2004, the Hurricanes have yet to win a conference title, although they reached the title game in 2017. Last season, Miami finished third in the conference at 6-2. Two other contenders for the ACC title are SMU and Louisville. The Mustangs made headlines by reaching the ACC Championship Game last year in their first season in the conference. SMU finished with a perfect 8-0 conference record, making history as the first team to reach a title game in its inaugural season in a power conference since the National Championship Game era began in 1998. Louisville, while still seeking its first ACC title, reached the championship game in 2023, only to lose to Florida State. The Cardinals ended last season with a 5-3 conference record, tied for fourth place with Syracuse, Georgia Tech and Duke. Want great stories delivered right to your inbox? Create or log in to your FOX Sports account, and follow leagues, teams and players to receive a personalized newsletter daily!
Newsweek
6 hours ago
- Sport
- Newsweek
ACC Football Betting Odds, Picks: Reigning Champ Clemson Heavily Favored
Oddsmakers see coach Mario Cristobal's Miami Hurricanes as the biggest threat to Clemson in the ACC in 2025. Oddsmakers see coach Mario Cristobal's Miami Hurricanes as the biggest threat to Clemson in the ACC in 2025. Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Fans of ACC football will not be surprised to see how oddsmakers view this conference in 2025. A year after Florida State, Clemson and Miami all entered 2024 with legit conference title hopes (at least according to oddsmakers), the odds right now indicate that it will be Clemson and then everyone else this fall. 2025 ACC Championship Game Winner Odds DK FD bet365 Clemson +105 +110 +110 Miami +380 +400 +400 Louisville +850 +800 +800 SMU +850 +900 +800 Georgia Tech +1200 +1300 +1200 Duke +2500 +2600 +2500 Florida State +2800 +3100 +2800 Virginia Tech +3500 +4800 +4000 NC State +4500 +4100 +4000 Pittsburgh +4500 +4200 +4000 North Carolina +4000 +4500 +2800 The Tigers, who have won the ACC title in nine of the last 11 seasons, are just shorter than even-money at most sportsbooks. Most books list second-favorite Miami at 4-to-1, though DK is slightly more bullish on the Canes. Louisville and reigning ACC runner-up SMU have the next-best chances to upend Clemson. Neither, however, are seen as serious threats. The Mustangs' and Cardinals' 8-to-1 or longer odds translate to around an 11 percent chance of winning the conference. Clemson, Boise Biggest League Favorites In CFB It's worth noting that across all of college football, the only conference race that oddsmakers see as less intriguing than the ACC is the Mountain West, where Boise State is minus-money (-140 at DK, -145 at FanDuel). We're not breaking ground by pointing out that the SEC, Big Ten and Big 12 are much more balanced than the ACC. Still, the odds on the favorites in those conferences drive home just how shallow the ACC appears to be this year. While Clemson is +110 or shorter to win this league, SEC favorite Texas is +250 or longer across the board and reigning national champ Ohio State is a bit shorter than 2-to-1 to win the Big Ten. In the Big 12, the five "favorites" all have odds between 5-to-1 and 7-to-1. For more perspective on the perceived depth of the ACC in 2025, keep in mind that last year, five teams -- Florida State, Clemson, Miami, NC State and Lousville -- had 8-to-1 or shorter odds to win the league in late July. 2025 ACC Betting Preview: 4 Burning Questions Will Loaded Clemson Tigers Dominate ACC? Whether you're picking the ACC winner based on who has the most experience, the most proven star power or the fewest holes, it's difficult to land on an anyone other than Clemson. The Tigers have a handful of stars on both sides of the ball, including one of the Heisman favorites at QB. Signal-caller Cade Klubnik, WR Antonio Williams and OT Blake Miller could all be first-round picks in the 2025 NFL Draft. This year's Clemson D arguably boasts even more NFL talent: D-linemen Peter Woods and T.J. Parker are likely top-10 NFL Draft picks next spring, while linebackers Wade Woodaz and Sammy Brown were named to USA TODAY Sports Network's preseason All-ACC football team. In the secondary, CB Avieon Terrell is yet another potential future first-rounder after earning All-ACC second-team honors as a sophomore last fall. Though it will spoil the answers to the other "questions" in this piece, I'll go ahead and say that no, I don't see anyone other than Clemson -- which is among five teams in the country that are currently projected to be favored in every regular season game this year -- winning the ACC in 2025. Right now, Clemson is the rare example of a preseason conference favorite that is worth a wager at +110 or shorter. Can Miami Reach (Or Win) ACC Championship Game? Hurricanes coach Mario Cristobal has had no problems on the recruiting front in Coral Gables. Per 247 Sports, he landed the No. 16 recruiting class in '22, followed by top-10 classes in both '23 (No. 7) and '24 (No. 4), as well as the No. 14 class in '25. Miami's average class rank over the last four years is just outside the top 10 in the nation at 10.25, and it's even better than Clemson's average rank of 14.5 over the same period. But Cristobal's first three teams at The U have gone 5-7 (3-5 ACC) in 2022, 7-6 (3-5 ACC) in 2023 and 10-3 (6-2 ACC) in 2024. With one of the top transfer QBs in the nation, Carson Beck, among a handful of future pros on this roster, Miami has the talent -- on paper, at least -- to push Clemson. The Canes were the highest-scoring team in the country a year ago, but they will be lacking in proven experience in 2025, especially at the skill positions. In addition to losing No. 1 overall pick Cam Ward under center, top running back Damien Martinez, second-team All-ACC tight end Elijah Arroyo and first-team All-ACC wide receiver Xavier Restrepo all have to be replaced. Beck will throwing to an entirely overhauled wide receiver group. None of Miami's top six pass-catchers from a year ago are back. This team does, however, have two quality running backs returning. Mark Fletcher Jr. averaged 5.4 yards per carry in 2024, while Jordan Lyle averaged 7.4 ypc, and the O-line led by projected first-round tackle Francis Mauigoa should be solid. Defensively, the Canes have room to improve after allowing 25.3 points per game last year. Miami lost LB Francisco Mauigoa and DE Tyler Baron to the 2025 NFL Draft, and 2024 first-team All-ACC DT Simeon Barrow Jr. and second-team all-conference safety Mishael Powell are battling for NFL roster spots right now. Schedule-wise, one wrinkle that is good for Clemson and Miami -- but bad for anyone hoping for a surprise ACC Championship Game matchup -- is that the Canes and Tigers will not face each other in the regular season. Could Louisville, SMU Or Anyone Else Make Noise? Remember, last year, it was SMU -- not Miami -- that ended up battling Clemson in a thrilling ACC title game. The Mustangs' outstanding debut season in this league was enough to give the ACC two teams in the 12-team College Football Playoff field. SMU should once again be high-scoring in its second season in this conference, as dynamic QB Kevin Jennings could push Klubnik for the honor of the conference's top QB. The Mustangs have a tough schedule and a lot of outgoing talent to replace, but they're as tempting as anyone besides Clemson (though that's not to say that I expect them to beat the Tigers in Death Valley on October 18). Like SMU and Miami, Louisville is projected to be explosive on offense. The Cardinals defense is a question mark, though. Louisville added a high-upside passer from the portal: former USC Trojan Miller Moss. Coach Jeff Brohm figures to have a solid offense in Year 3 of his tenure. The Cardinals averaged 30.7 points per game with Jack Plummer under center in 2023 and 36.5 ppg with another veteran transfer QB, Tyler Shough, in 2024. Still, there are too many questions on this roster for me to back Louisville right now, even though they handed Clemson its only conference loss of 2024. Oddsmakers see Georgia Tech and Duke as the next-biggest threats to Clemson and Miami. Either the Yellow Jackets or Blue Devils -- who went a combined 16-10 (10-6 ACC) a year ago -- could conceivably win enough games to reach the ACC Championship Game, especially if it doesn't all come together for Miami. That being said, neither Duke nor Georgia Tech quite strike me as a legit conference title contender this year. Will Mike Norvell's Seminoles Bounce Back? Obviously, it's hard to imagine 2023 conference champ FSU contending for an ACC title in 2025 after a catastrophic, 2-10 (1-7 ACC) 2024 campaign. But in a conference that looks wide-open after Clemson, the Noles could be a factor if former BC QB Thomas Castellanos and offensive coordinator Guz Malzahn can spark the offense. FSU went from one of the best offensive teams in the nation with Jordan Travis at QB in 2023 (34.6 points per game) to one of the worst in the country under QB D.J. Uiagalelei last year (15.4). This year's squad does feature several high-upside portal additions in WRs Duce Robinson and Squirrel White from USC and Tennessee, respectively, plus ex-Oklahoma RB Gavin Sawchuk. Newsweek may earn an affiliate commission if you sign up through the links in this article. See the sportsbook operator's terms and conditions for important details. Sports betting operators have no influence over newsroom coverage.
Business Upturn
10 hours ago
- Business
- Business Upturn
Adrenocortical Carcinoma Market Forecast upto 2034—Insights into Emerging Therapies and Market Trends
New York, USA, July 29, 2025 (GLOBE NEWSWIRE) — Adrenocortical Carcinoma Market Forecast upto 2034—Insights into Emerging Therapies and Market Trends | DelveInsight The adrenocortical carcinoma market in the 7MM is anticipated to boost during the forecast period (2025–2034), due to the launch of emerging therapies such as CY‑101 from Cytovation and OR‑449 from Orphagen Pharmaceuticals, and others, and the increasing cases of ACC. DelveInsight's Adrenocortical Carcinoma Market Insights report includes a comprehensive understanding of current treatment practices, emerging adrenocortical carcinoma drugs, market share of individual therapies, and current and forecasted adrenocortical carcinoma market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Adrenocortical Carcinoma Market Report According to DelveInsight's analysis, the total adrenocortical carcinoma market size is expected to grow from USD 30 million in the 7MM in 2024. in the 7MM in 2024. The United States accounts for the largest market size of adrenocortical carcinoma, in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan. Based on DelveInsight's assessment in 2024, the 7MM had 1,250 incident cases of ACC, and it is projected that these cases will experience an increasing growth trend with a significant CAGR during the forecast period (2025−2034). incident cases of ACC, and it is projected that these cases will experience an increasing growth trend with a significant CAGR during the forecast period (2025−2034). Prominent companies, including GlaxoSmithKline, Bristol Myers Squibb, Merck, Cytovation, Enterome, Orphagen Pharmaceuticals, and others, are actively working on innovative adrenocortical carcinoma drugs. and others, are actively working on innovative adrenocortical carcinoma drugs. Some of the key adrenocortical carcinoma therapies in the pipeline include CY-101, OR-449, dostarlimab, nivolumab + ipilimumab, and pembrolizumab, EO2401 + Nivolumab, and others. These novel adrenocortical carcinoma therapies are anticipated to enter the adrenocortical carcinoma market in the forecast period and are expected to change the market. Discover which adrenocortical carcinoma medications are expected to grab the market share @ Adrenocortical Carcinoma Market Report Adrenocortical Carcinoma Market Dynamics The adrenocortical carcinoma market dynamics are anticipated to change in the coming years. The availability of surgical options such as adrenalectomy provides a practical approach for removing the diseased adrenal gland, thereby improving access to treatment. Mitotane remains the mainstay treatment for ACC, with its exclusive status as an 'Off-Patent, Off-Exclusivity Drug without an Approved Generic' in the Orange Book reinforcing its dominant position. There is significant potential for collaboration among medical professionals, researchers, and patient advocacy organizations to raise disease awareness and broaden access to care. The limited therapeutic landscape for ACC presents a strategic opportunity for new players to enter and expand within the market. Furthermore, many potential therapies are being investigated for the treatment of adrenocortical carcinoma, and it is safe to predict that the treatment space will significantly impact the adrenocortical carcinoma market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the adrenocortical carcinoma market in the 7MM. However, several factors may impede the growth of the adrenocortical carcinoma market. The reliance on surgery as the main treatment for ACC, due to the limited availability of systemic therapies, highlights a weakness stemming from a lack of diverse treatment options. ACC's rarity and the small number of affected patients make it difficult to conduct large-scale clinical trials, complicating the development of evidence-based treatment protocols and assessment of new therapies. Resistance to current treatments like mitotane monotherapy, or their limited effectiveness, often leads to poor patient outcomes and represents a major challenge. Additionally, the ultra-rare nature of ACC limits access to funding and resources for research and development, posing a significant barrier to progress. Moreover, adrenocortical carcinoma treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the adrenocortical carcinoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the adrenocortical carcinoma market growth. Adrenocortical Carcinoma Treatment Market Surgical removal is the primary treatment option for localized adrenocortical carcinoma. However, many patients are diagnosed at advanced stages, where surgery alone is unlikely to be curative. Chemotherapy, particularly mitotane, is the only FDA-approved drug for ACC, though its effectiveness varies, and it often causes substantial side effects. Complete surgical excision remains the only potentially curative option. For localized cases, adjuvant therapies are used to reduce the risk of recurrence. In cases where the tumor is unresectable or has metastasized, treatment shifts to palliative care. First-line treatment strategies for ACC are personalized, taking into account the patient's prognostic profile. For those with good performance status and aggressive disease, a combination regimen like EDP-M (etoposide, doxorubicin, cisplatin, and mitotane) is often employed. Patients with less aggressive disease may be treated with mitotane alone, sometimes alongside locoregional interventions. Despite some efficacy, EDP-M is not curative, and the overall prognosis remains poor. Second-line options such as streptozocin with mitotane (S+M) and gemcitabine with capecitabine (G+C) show limited effectiveness, with response rates around 10%. G+C is generally well tolerated but lacks strong molecular predictors of response. Temozolomide, used as a third-line option, shows anti-cancer activity in laboratory settings. While some patients experience disease stabilization, its clinical benefit is modest, and research is ongoing to determine which patient subgroups may respond best. Looking ahead, future treatment advances may include new chemotherapies, angiogenesis inhibitors, and targeted small-molecule drugs. These innovations, driven by deeper molecular insights into ACC biology, offer potential for improved therapeutic outcomes. Learn more about the adrenocortical carcinoma treatment options @ Adrenocortical Carcinoma Drugs Market Adrenocortical Carcinoma Emerging Drugs and Companies Research and development efforts in adrenocortical carcinoma remain limited due to its classification as an ultra-rare disease, resulting in a sparse pipeline with only a few therapies currently in Phase II, Phase I/II, or preclinical stages. Among the investigational treatments being evaluated in clinical trials are Dostarlimab (GlaxoSmithKline), the combination of Nivolumab and Ipilimumab (Bristol Myers Squibb), Pembrolizumab (Merck), CY-101 (Cytovation), EO2401 combined with Nivolumab (Enterome/Bristol Myers Squibb), OR-449 (Orphagen Pharmaceuticals), and others. CY-101 is designed to selectively attack and destabilize cancer cell membranes, which leads to the release of tumor-specific neoantigens and enables the immune system to launch a targeted, systemic response against the cancer. In addition, CY-101 blocks the β-catenin signaling pathway, thereby impeding tumor progression and further activating immune defenses. Currently being developed by Cytovation, CY-101 is slated to enter a multi-national Phase II clinical trial for adrenocortical carcinoma in late 2025, with initial data expected in 2026. This study is being conducted in collaboration with Cancer Research UK and the Norwegian Cancer Society, as announced in January 2025. OR-449 is a first-in-class, orally available inhibitor of the orphan nuclear receptor steroidogenic factor-1 (SF-1, NR5A1), a validated target in ACC—a rare and difficult-to-treat adrenal gland cancer. The U.S. FDA has granted OR-449 Rare Pediatric Disease Designation (RPDD) to support its expedited development for pediatric ACC. Additionally, Orphagen has secured a $10.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to fund its IND application and a Phase I trial in adults with ACC. The grant spans three years and requires Orphagen to raise matching funds. Pembrolizumab, a widely approved PD-1 checkpoint inhibitor, is under evaluation in a Phase II trial for patients with advanced ACC. The trial, sponsored by Memorial Sloan Kettering Cancer Center, is currently in the 'active, not recruiting' phase. EO2401, a novel microbiome-based therapeutic vaccine developed by Enterome, was aimed at treating solid tumors such as glioblastoma and ACC. However, in November 2024, its Phase I/II SPENCER trial was terminated due to strategic considerations. This development marks a setback in the search for innovative treatments targeting ACC. The anticipated launch of these emerging adrenocortical carcinoma therapies are poised to transform the adrenocortical carcinoma market landscape in the coming years. As these cutting-edge adrenocortical carcinoma therapies continue to mature and gain regulatory approval, they are expected to reshape the adrenocortical carcinoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about new treatment for adrenocortical carcinoma, visit @ Adrenocortical Carcinoma Management Recent Developments in the Adrenocortical Carcinoma Market In April 2025, Cytovation announced that it had raised NOK62 million (USD 6 million) largely from existing investors, led by Sandwater. These funds will be used to advance CY-101 into a multi-national Phase II clinical trial in patients with ACC. announced that it had raised NOK62 million (USD 6 million) largely from existing investors, led by Sandwater. These funds will be used to advance CY-101 into a multi-national Phase II clinical trial in patients with ACC. In November 2024, the status of the Phase I/II SPENCER study was updated to 'terminated,' with the reason cited as a strategic decision. This termination represents a setback in the emerging prospects for developing therapies for ACC. Adrenocortical Carcinoma Overview Adrenocortical carcinoma (ACC) is a rare and aggressive cancer that originates in the cortex of the adrenal glands, which are located above the kidneys and are responsible for producing essential hormones such as cortisol, aldosterone, and androgens. ACC can occur at any age but is most commonly diagnosed in children under 5 and adults in their 40s and 50s. The exact causes of ACC are not well understood, but it has been associated with certain genetic syndromes, including Li-Fraumeni syndrome, Beckwith-Wiedemann syndrome, and multiple endocrine neoplasia type 1 (MEN1), which suggests a hereditary component in some cases. Symptoms of ACC can vary depending on whether the tumor is functioning (hormone-producing) or non-functioning. Functioning tumors may cause signs of hormone excess, such as Cushing's syndrome (weight gain, high blood pressure, muscle weakness, and skin changes), virilization in women (facial hair, deepened voice), or feminization in men. Non-functioning tumors may present later and often manifest as abdominal pain, a palpable mass, or symptoms related to tumor spread, such as weight loss or back pain. Diagnosis of ACC typically involves a combination of imaging studies and laboratory tests. Imaging techniques such as CT scans or MRI help identify the size, location, and potential spread of the tumor. Hormonal blood and urine tests assess whether the tumor is producing excess hormones. A definitive diagnosis is usually confirmed through histological examination of tissue obtained via biopsy or after surgical removal of the tumor. Early detection is crucial, as ACC often presents at an advanced stage and has a poor prognosis if not treated promptly. Adrenocortical Carcinoma Epidemiology Segmentation The adrenocortical carcinoma epidemiology section provides insights into the historical and current adrenocortical carcinoma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The adrenocortical carcinoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Incident Cases of ACC Stage-specific Incident Cases of ACC Gender-specific Incident Cases of ACC Age-specific Incident Cases of ACC Download the report to understand which factors are driving adrenocortical carcinoma epidemiology trends @ Adrenocortical Carcinoma Treatment Algorithm Adrenocortical Carcinoma Report Metrics Details Study Period 2020–2034 Adrenocortical Carcinoma Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Adrenocortical Carcinoma Market Size in 2024 USD 30 Million Key Adrenocortical Carcinoma Companies GlaxoSmithKline, Bristol Myers Squibb, Merck, Cytovation, Enterome, Orphagen Pharmaceuticals, and others Key Adrenocortical Carcinoma Therapies CY-101, OR-449, dostarlimab, nivolumab + ipilimumab, and pembrolizumab, EO2401 + Nivolumab, and others Scope of the Adrenocortical Carcinoma Market Report Adrenocortical Carcinoma Therapeutic Assessment: Adrenocortical Carcinoma current marketed and emerging therapies Adrenocortical Carcinoma current marketed and emerging therapies Adrenocortical Carcinoma Market Dynamics: Conjoint Analysis of Emerging Adrenocortical Carcinoma Drugs Conjoint Analysis of Emerging Adrenocortical Carcinoma Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Adrenocortical Carcinoma Market Access and Reimbursement Discover more about adrenocortical carcinoma drugs in development @ Adrenocortical Carcinoma Clinical Trials Table of Contents 1. Adrenocortical Carcinoma Market Key Insights 2. Adrenocortical Carcinoma Market Report Introduction 3. Adrenocortical Carcinoma Market Overview at a Glance 4. Adrenocortical Carcinoma Market Executive Summary 5. Disease Background and Overview 6. Adrenocortical Carcinoma Treatment and Management 7. Adrenocortical Carcinoma Epidemiology and Patient Population 8. Patient Journey 9. Adrenocortical Carcinoma Marketed Drugs 10. Adrenocortical Carcinoma Emerging Drugs 11. Seven Major Adrenocortical Carcinoma Market Analysis 12. Adrenocortical Carcinoma Market Outlook 13. Potential of Current and Emerging Therapies 14. KOL Views 15. Unmet Needs 16. SWOT Analysis Related Reports Adrenocortical Carcinoma Pipeline Adrenocortical Carcinoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key adrenocortical carcinoma companies, including Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis, Ipsen, Genentech, among others. Congenital Adrenal Hyperplasia Market Congenital Adrenal Hyperplasia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key congenital adrenal hyperplasia companies, including Crinetics Pharmaceuticals Inc., Diurnal Limited, Adrenas Therapeutics Inc, Neurocrine Biosciences, Spruce Biosciences, among others. Congenital Adrenal Hyperplasia Pipeline Congenital Adrenal Hyperplasia Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key congenital adrenal hyperplasia companies, including Neurocrine Biosciences, Spruce Biosciences, Adrenas Therapeutics Inc., Crinetics Pharmaceuticals, Diurnal, among others. Cushing's Syndrome Market Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Cushing's syndrome companies including Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Connect with us on LinkedIn|Facebook|Twitter Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Fox Sports
10 hours ago
- Sport
- Fox Sports
2025 College Football Odds: Which Team Will Claim The ACC Title?
The ACC boasts more than just Clemson. Fans saw that last year with SMU and Miami (FL). So, beyond the Tigers, which other teams do oddsmakers think will have a shot at the conference title this year? Let's take a look ahead at the 2025 ACC title odds at DraftKings Sportsbook as of July 29. ACC Winner 2025-26 Clemson: +105 (bet $10 to win $20.50 total) Miami FL: +380 (bet $10 to win $48 total) SMU: +850 (bet $10 to win $95 total) Louisville: +850 (bet $10 to win $95 total) Georgia Tech: +1200 (bet $10 to win $130 total) Duke: +2500 (bet $10 to win $260 total) Florida State: +2800 (bet $10 to win $290 total) Virginia Tech: +3500 (bet $10 to win $360 total) North Carolina: +4000 (bet $10 to win $410 total) Pittsburgh: +4500 (bet $10 to win $460 total) NC State: +4500 (bet $10 to win $460 total) Syracuse: +7000 (bet $10 to win $710 total) Virginia: +8000 (bet $10 to win $810 total) Boston College: +8000 (bet $10 to win $810 total) California: +15000 (bet $10 to win $1,510 total) Wake Forest: +50000 (bet $10 to win $5,010 total) Stanford: +50000 (bet $10 to win $5,010 total) The Tigers have won the ACC nine times since 2011, and they are favored to win the title again this season. Following a dramatic 34-31 victory over SMU in last year's ACC Championship Game, the Tigers have 80% of their roster returning — the highest percentage in the nation, according to ESPN research. Last season, Clemson finished second in the conference with a 7-1 record. Next on the oddsboard is the University of Miami. Since joining the ACC in 2004, the Hurricanes have yet to win a conference title, although they reached the title game in 2017. Last season, Miami finished third in the conference at 6-2. Two other contenders for the ACC title are SMU and Louisville. The Mustangs made headlines by reaching the ACC Championship Game last year in their first season in the conference. SMU finished with a perfect 8-0 conference record, making history as the first team to reach a title game in its inaugural season in a power conference since the National Championship Game era began in 1998, according to ESPN research. Louisville, while still seeking its first ACC title, reached the championship game in 2023, only to lose to Florida State. The Cardinals ended last season with a 5-3 conference record, tied for fourth place with Syracuse, Georgia Tech and Duke. Want great stories delivered right to your inbox? Create or log in to your FOX Sports account , and follow leagues, teams and players to receive a personalized newsletter daily! recommended Item 1 of 3 Get more from the College Football Follow your favorites to get information about games, news and more in this topic
